Isabella Orienti

ORCID

Publication Activity (10 Years)

Years Active: 2019-2024
Publications (10 Years): 11

Top Venues

Pharmaceutics

International journal of nanomedicine

Drug design, development and therapy

International journal of molecular sciences

Università degli Studi di Bologna

This page only lists publications with an associated author ORCID identifier.

Affiliation History

Università degli Studi di Bologna

Italy

Full Professor :: Pharmacy and Biotechnology

Publications

Cristina Matteo, Isabella Orienti, Adriana Eramo, Ann Zeuner, Mariella Ferrari, Alice Passoni, Renzo Bagnati, Marianna Ponzo, Ezia Bello, Massimo Zucchetti, Roberta Frapolli
Validated LC-MS/MS Assay for the Quantitative Determination of Fenretinide in Plasma and Tumor and Its Application in a Pharmacokinetic Study in Mice of a Novel Oral Nanoformulation of Fenretinide. Pharmaceutics 16 (3) (2024)
Cristina Matteo, Isabella Orienti, Adriana Eramo, Ann Zeuner, Mariella Ferrari, Alice Passoni, Renzo Bagnati, Marianna Ponzo, Ezia Bello, Massimo Zucchetti, Roberta Frapolli
Validated LC-MS/MS Assay for the Quantitative Determination of Fenretinide in Plasma and Tumor and Its Application in a Pharmacokinetic Study in Mice of a Novel Oral Nanoformulation of Fenretinide. Pharmaceutics 16 (3) (2024)
Cristina Matteo, Isabella Orienti, Adriana Eramo, Ann Zeuner, Mariella Ferrari, Alice Passoni, Renzo Bagnati, Marianna Ponzo, Ezia Bello, Massimo Zucchetti, Roberta Frapolli
Validated LC-MS/MS Assay for the Quantitative Determination of Fenretinide in Plasma and Tumor and Its Application in a Pharmacokinetic Study in Mice of a Novel Oral Nanoformulation of Fenretinide. Pharmaceutics 16 (3) (2024)
Lucrezia Galassi, Martina Rossi, Pietro Lodeserto, Monia Lenzi, Francesca Borsetti, Manuela Voltattorni, Giovanna Farruggia, Paolo Blasi, Isabella Orienti
Naxitamab Activity in Neuroblastoma Cells Is Enhanced by Nanofenretinide and Nanospermidine. Pharmaceutics 15 (2) (2023)
Lucrezia Galassi, Martina Rossi, Pietro Lodeserto, Monia Lenzi, Francesca Borsetti, Manuela Voltattorni, Giovanna Farruggia, Paolo Blasi, Isabella Orienti
Naxitamab Activity in Neuroblastoma Cells Is Enhanced by Nanofenretinide and Nanospermidine. Pharmaceutics 15 (2) (2023)
Lucrezia Galassi, Martina Rossi, Pietro Lodeserto, Monia Lenzi, Francesca Borsetti, Manuela Voltattorni, Giovanna Farruggia, Paolo Blasi, Isabella Orienti
Naxitamab Activity in Neuroblastoma Cells Is Enhanced by Nanofenretinide and Nanospermidine. Pharmaceutics 15 (2) (2023)
Lucrezia Galassi, Martina Rossi, Pietro Lodeserto, Monia Lenzi, Francesca Borsetti, Manuela Voltattorni, Giovanna Farruggia, Paolo Blasi, Isabella Orienti
Naxitamab Activity in Neuroblastoma Cells Is Enhanced by Nanofenretinide and Nanospermidine. Pharmaceutics 15 (2) (2023)
Rosa Luisa Potenza, Pietro Lodeserto, Isabella Orienti
Fenretinide in Cancer and Neurological Disease: A Two-Face Janus Molecule. International journal of molecular sciences 23 (13) (2022)
Pietro Lodeserto, Martina Rossi, Paolo Blasi, Giovanna Farruggia, Isabella Orienti
Nanospermidine in Combination with Nanofenretinide Induces Cell Death in Neuroblastoma Cell Lines. Pharmaceutics 14 (6) (2022)
Isabella Orienti, Giovanna Farruggia, Ferro Nguyen, Peng Guan, Natalia Calonghi, Venkatadri Kolla, Michael Chorny, Garrett M Brodeur
Nanomicellar Lenalidomide-Fenretinide Combination Suppresses Tumor Growth in an MYCN Amplified Neuroblastoma Tumor. International journal of nanomedicine 15 (2020)
Isabella Orienti, Ferro Nguyen, Peng Guan, Venkatadri Kolla, Natalia Calonghi, Giovanna Farruggia, Michael Chorny, Garrett M Brodeur
A Novel Nanomicellar Combination of Fenretinide and Lenalidomide Shows Marked Antitumor Activity in a Neuroblastoma Xenograft Model. Drug design, development and therapy 13 (2019)

Isabella Orienti.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

Isabella Orienti